GlassScriptPhysician profile
Matthew Berwager
NPI 1275178691
$4,659.04
in general payments reported to CMS, 2019-2025
26 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,841 · 2022: $1,823 · 2023: $685 · 2024: $106 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $994.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $994.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $524.39 | 2021-2024 | Xarelto |
| Pfizer INC. | $444.24 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.54 | 2021-2023 | Jardiance |
| United Therapeutics Corporation | $364.65 | 2021-2022 | |
| Cvrx, INC. | $360.59 | 2021-2025 | Barostim Neo System |
| Amgen INC. | $301.60 | 2021-2024 | Repatha |
| Merck Sharp & Dohme LLC | $282.01 | 2021-2024 | Verquvo |
| Esperion Therapeutics, INC. | $229.97 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $191.81 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $190.36 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $185.21 | 2021-2023 | Optimizer |
| Kestra Medical Technology Services, INC. | $184.32 | 2025 | Assure Wcd |
| Abbott Laboratories | $175.44 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.20 | 2021-2022 | |
| Atricure, INC. | $117.35 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $101.76 | 2021-2022 | |
| Novo Nordisk INC | $84.70 | 2021-2023 | Ozempic |
| Alnylam Pharmaceuticals INC. | $79.00 | 2023 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $70.03 | 2022-2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $55.81 | 2021-2023 | Farxiga |
| Vifor Pharma, INC. | $48.14 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $45.71 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $44.28 | 2023 | Inpefa |
| Arbor Pharmaceuticals, INC. | $26.70 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $18.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.26 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Berwager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.